Sara Peralta Flores

Dr. Sara Peralta Flores

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Climacteric
Verified
Journal Article
Closed access
Camil Castelo-BrancoCamil Castelo-Branco
Camil Castelo-Branco
SFSara Peralta Flores
Sara Peralta Flores
JFJ. Ferrer
J. Ferrer
SGSantiago Palacios Gil-Antuñano
Santiago Palacios Gil-Antuñano
SCS. Cornago
S. Cornago
FQFrancisco Quereda
Francisco Quereda
An important goal in menopause research is to develop knowledge and identify interventions that strive to promote, maintain and enhance well-being for women. To evaluate the knowledge of postmenopausal Spanish women about menopause and their knowledge of and trust in hormone replacement therapy (HRT) and to identify their sources of information and how those data are related to compliance with their prescription. A total of 270 symptomatic postmenopausal women were personally interviewed using a structured questionnaire, which was designed to collect information on their familiarity with medical menopause studies, the menopause and the effects of HRT, their knowledge of alternative therapies, and to identify their sources of information. The most well-known menopausal complaints were hot flushes, sweats, irregular menstruation, cessation of menstruation, irritability and mood changes. Following suggestions of other symptoms by the interviewer, other complaints such as vaginal dryness, insomnia and depression/anxiety were also mentioned. HRT and phytoestrogens were recognized as treatments for the climacteric by most of the women. A woman's decision to seek treatment was initiated in 77% of cases by the gynecologist, in 12% by the general practitioner, in 3% by friends/family and in 3% by books/magazines. The most frequent responses of women to the onset of menopausal symptoms were to talk with their partner (39%), to discuss it with their gynecologist (33%) or with their general practitioner (14%) and to talk with their friends/family or to read books/magazines (10%). Vasomotor symptoms are recognized as the main complaint during the climacteric and HRT and phytoestrogens as the main therapies. Gynecologists play an important role in assuring compliance with therapies related to the menopause.

1 August 2024 in Genes
Verified
Journal Article
Open access
PDF file
ISInés Agusti Sunyer
Inés Agusti Sunyer
MJMarta Méndez Justo
Marta Méndez Justo
ACAina Borras Capo
Aina Borras Capo
ACAnna Goday Cibeira
Anna Goday Cibeira
GLGUIMERA LEAL
GUIMERA LEAL
DMDolors Manau
Dolors Manau
The relationship between premature ovarian insufficiency (FXPOI) and premutation in the FMR1 gene is well established. In recent years, though, a potential relationship between the latter and a low ovarian reserve has been suggested. To explore it, we conducted a retrospective study in an IVF program at a university tertiary referral center in Barcelona (Spain). Data were obtained retrospectively from a total of 385 women referred for FMR1 gene testing at our institution from January 2018 to December 2021. We compared the prevalence of FMR1 gene premutation between 93 of them, younger than 35 years, with a diminished ovarian reserve (DOR), characterized by levels of anti-Mullerian hormone < 1.1 ng/mL and antral follicle count < 5; and 132 egg donors screened by protocol that served as the controls. We found a higher prevalence of FMR1 premutation in the DOR group (seven patients (7.69%)) than in the control group (one patient (1.32%)), Fisher-exact test p-value = 0.012). We concluded that compared with the general population represented by young egg donors, the prevalence of FMR1 gene premutation is higher in young patients with a diminished ovarian reserve. Although these findings warrant further prospective validation in a larger cohort of patients within DOR, they suggest that, in clinical practice, FMR1 premutation should be determined in infertile young patients with DOR in order to give them adequate genetic counselling.

14 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
ISInés Agusti Sunyer
Inés Agusti Sunyer
RWRobin Wijngaard
Robin Wijngaard
EBEstefanía Martínez Barrios
Estefanía Martínez Barrios
TBTamara Barcos
Tamara Barcos
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
Female FMR1 (Fragile X mental retardation 1) premutation carriers are at risk for developing fragile X-associated primary ovarian insufficiency (FXPOI), a condition characterized by amenorrhea before age 40 years. Not all women with a FMR1 premutation suffer from primary ovarian insufficiency and nowadays there are no molecular or other biomarkers that can help predict the occurrence of FXPOI. Long non-coding RNAs (lncRNAs) comprise a group of regulatory transcripts which have versatile molecular functions, making them important regulators in all aspects of gene expression. In recent medical studies, lncRNAs have been described as potential diagnostic biomarkers in many diseases. The present study was designed to determine the expression profile of three lncRNAs derived from the FMR1 locus, FMR4, FMR5 and FMR6, in female FMR1 premutation carriers in order: (i) to determine a possible role in the pathogenesis of FXPOI and (ii) to investigate whether they could serve as a biomarker for the diagnosis of FXPOI. FMR4, FMR5 and FMR6 transcripts levels were evaluated in total RNA extracted from peripheral blood by digital droplet PCR and compared between FMR1 premutation carriers with FXPOI and without FXPOI. The diagnostic value of lncRNAs was evaluated by receiver operating characteristic (ROC) analysis. Results revealed a significant association between FXPOI and high expression levels of FMR4. No association was obtained for FMR5 or FMR6. ROC curve analysis revealed that FMR4 can distinguish FMR1 premutation carrier with FXPOI with a diagnostic power of 0.67. These findings suggest a potential role of FMR4 as a possible biomarker for FXPOI.

Verified
Journal Article
Open access
PDF file
ACAnna Goday Cibeira
Anna Goday Cibeira
LVLaura Valls-Roca
Laura Valls-Roca
MJMarta Méndez Justo
Marta Méndez Justo
YCYolanda Cívico
Yolanda Cívico
MGMeritxell Gràcia
Meritxell Gràcia
DMDolors Manau
Dolors Manau
Endometriosis affects about 10% of reproductive-aged women, characterized by endometrial-like tissue outside the uterus, leading to chronic inflammation. The exact cause remains unknown, though genetic and epigenetic factors are increasingly recognized alongside traditional theories. The disease manifests in forms such as endometriomas, whether superficial or peritoneal, and deep infiltrating lesions, often causing chronic pain and infertility. Infertility affects nearly 50% of patients, requiring expensive treatments like in vitro fertilization. Oxidative stress plays a key role in endometriosis, with sirtuins, especially SIRT3, emerging as important regulators. SIRT3, located in mitochondria, helps manage oxidative stress and redox balance. Despite extensive research, no diagnostic biomarkers exist. This longitudinal study compares oxidative stress markers and SIRT3 levels in patients with different endometriosis types. While classic oxidative stress markers showed no significant differences, higher SIRT3 levels were observed in peripheral blood mononuclear cells of patients with deep endometriosis. Additionally, patients with prior surgeries had elevated SIRT3 levels, indicating a possible link between disease severity and SIRT3 expression. The findings suggest SIRT3 as a potential therapeutic target in endometriosis management.

30 March 2026 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
SFSara Peralta Flores
Sara Peralta Flores
BABaris Ata
Baris Ata
BLBarbara Lawrenz
Barbara Lawrenz
ASAnastasia Salame
Anastasia Salame
HFHuman M Fatemi
Human M Fatemi
Dear Editors, We congratulate Dhillon-Smith et al. for the retrospective study including >42 000 ART cycles comparing vaginal oil capsules with progesterone pessaries for luteal phase support. They report higher live birth rates and lower miscarriage rates with capsules ( Dhillon-Smith et al., 2026). However, we think that residual confounding due to differences in age, ovarian reserve, and embryo competence between the two groups substantially limits inference of superiority of one formulation over the other. Women in the pessary group were significantly older (median 36 vs 35 years), had lower anti-Müllerian hormone (AMH) (14.5 vs 15.2 pmol/l), and a lower antral follicle count (AFC) (13 vs 16) compared with women receiving capsules. They also had a higher prevalence of recurrent miscarriage (4.0% vs 3.5%). Despite some controversy, several studies, including our own recent study ( Lawrenz et al., 2025), suggest that diminished ovarian reserve is not only a quantitative issue but also qualitatively associated with lower euploidy rates independent of chronological age. In a pre-implantation genetic testing for aneuploidy (PGT-A) cohort, Li et al. observed that women with lower AMH had a significantly lower proportion of euploid blastocysts across age strata ( Li et al., 2023), indicating that AMH carries age-independent information about oocyte/embryo competence.

3 February 2022 in Medicina Reproductiva y Embriología Clínica
Verified
Journal Article
Closed access
AMAna Monzó
Ana Monzó
ACAna Casas
Ana Casas
ACAna Belén Castel
Ana Belén Castel
BGBeatriz Gaspar
Beatriz Gaspar
PLPlacido Llaneza
Placido Llaneza
CSClara Sanz
Clara Sanz